This trial is studying a new drug, apixaban, to see if it is safe and effective in treating myeloproliferative neoplasms (MPNs), which are blood disorders that occur when the body makes too many white or red blood cells, or platelets.
- Essential Thrombocythemia
- Polycythemia Vera
- Deep Vein Thrombosis (DVT)
- Myeloproliferative Neoplasms
- JAK2 V617F Mutation
- Primary Myelofibrosis
6 Primary · 7 Secondary · Reporting Duration: For the duration of the study follow-up period: 7 months
Awards & Highlights
2 Treatment Groups
Aspirin and cytoreductive therapy (if applicable)
1 of 2
Apixaban and cytoreductive therapy (if applicable)
1 of 2
46 Total Participants · 2 Treatment Groups
Primary Treatment: Apixaban 2.5 MG Oral Tablet [ELIQUIS] · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|The Ottawa Hospital||100.0%|
What portion of applicants met pre-screening criteria?
Frequently Asked Questions
Approximately how many individuals are engaged in this research?
"Affirmative. Clinical trials' website has published that this medical experiment, which was made public on February 17th 2021, is currently open for enrollment. A total of 46 individuals are desired from a single clinical facility." - Anonymous Online Contributor
Has the FDA given authorization to Apixaban 2.5 MG Oral Tablet [ELIQUIS] yet?
"The safety of Apixaban 2.5 MG Oral Tablet [ELIQUIS] has been evaluated as a two on the scale from one to three, given that this is a Phase II trial with some evidence for its security but no data confirming efficacy." - Anonymous Online Contributor
Is this an unprecedented clinical trial?
"Since its initial Phase 1 trial in 2005, sponsored by Abbott and involving 15480 patients, Apixaban 2.5 MG Oral Tablet [ELIQUIS] has been studied extensively with 207 active studies in 1452 cities across 62 countries leading to its approval for use as a medication." - Anonymous Online Contributor
What purposes does Apixaban 2.5 MG Oral Tablet [ELIQUIS] usually serve?
"Apixaban 2.5 MG Oral Tablet [ELIQUIS] is typically prescribed for deep vein thrombosis, but it may also be effective in mitigating death by myocardial infarction, back pain and after procedures such as percutaneous coronary intervention (PCI)." - Anonymous Online Contributor
Is access to this experiment available for prospective participants?
"According to the information posted on clinicaltrials.gov, recruitment for this medical study is still ongoing. The trial was initially created February 17th 2021 and recently modified April 19th 2022." - Anonymous Online Contributor